Thursday, February 29, 2024
Sarah Cannon Research Institute (SCRI), a renowned oncology research organization specializing in community-based clinical trials, has announced a collaboration with AstraZeneca, a global biopharmaceutical company known for its scientific advancements. This partnership aims to leverage innovative technology and operational efficiencies to improve the delivery of oncology clinical trials.
Through this collaboration, SCRI and AstraZeneca plan to implement advanced solutions to expedite clinical trial timelines, ease site burdens, and enhance enrollment rates across the United States.
Genospace, a leading precision medicine platform, has collaborated with SCRI Development Innovations to develop a proprietary technology called EHR2EDC (E2E). This technology seamlessly integrates data from Electronic Health Records (EHR) to Electronic Data Capture (EDC) systems for clinical trial data collection. E2E has demonstrated significant reductions in site-based data entry time, manual labor, monitoring costs, and improvements in data quality and decision-making processes for clinical trials.
The evolution of E2E and the implementation of SCRI's new operational model will synchronize end-to-end clinical research management, connecting over 1,300 physicians and providing access to clinical trials across multiple tumor types at more than 250 locations across 24 states in the U.S.
Dee Anna Smith, Chief Executive Officer of SCRI, highlighted the transformative potential of improving end-to-end research operations. She stated that the collaboration with AstraZeneca could accelerate efforts to bring innovative therapies to a broader population of cancer patients through a larger network of physicians.
Michele Sample, Vice President of Clinical Operations in Oncology R&D at AstraZeneca, emphasized the company's commitment to personalized and effective medical interventions for individuals with cancer. She noted that the partnership with SCRI aims to enhance U.S. enrollment and streamline clinical trial data collection, ultimately diversifying clinical trial participants and expediting trial timelines.
In essence, this collaboration represents a significant step forward in advancing cancer research and underscores a shared commitment to revolutionizing clinical trial execution for the benefit of patients worldwide.
Source: businesswire.com
